Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes
Randomized Double Blind Placebo-Controlled Study to Determine if Prophylaxis With RTB101 Compared to Placebo Reduces Severity of Lab Confirmed COVID19 in Adults ≥65 Years in a Nursing Home in Which ≥1 Person(s) Have Lab Confirmed COVID19
Sponsor: Restorbio Inc.
Terminated
Insufficient accrual rate
Other COVID19 trials with similar outcome
Listed as NCT04409327, this PHASE2 trial focuses on COVID19 and remains terminated or withdrawn. Sponsored by Restorbio Inc., it has been updated 8 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Mar 2021 — Jul 2024 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Phase: PHASE3 → PHASE2
▶ Show 3 earlier versions
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE3
-
Aug 2020 — Nov 2020 [monthly]
Recruiting PHASE3
-
Jul 2020 — Aug 2020 [monthly]
Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Restorbio Inc.
For direct contact, visit the study record on ClinicalTrials.gov .